New data highlights the clinical impact of the MiniMed™ 780G system in Asia Pacific

Medtronic, a global leader in healthcare technology, today shared new clinical and real-world evidence on the MiniMed™ 780G system from the Asia Pacific region demonstrating its ability to tackle high-carb diets while outperforming international guidelines for diabetes management. The data will be presented at the 1st Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Diets in the Asia Pacific regions traditionally feature high carbohydrate dishes, which can prove difficult to dose for given challenges in estimating the amount of carbohydrates in a meal and the associated need for taking the appropriate amount of insulin. When a dose is missed, high carbohydrate diets can lead to significant spikes in glucose, increasing the risk of both short and long-term complications.¹ With the MiniMed™ 780G system's Meal Detection™ technology - an advanced feature that uses current and past sugar trends to detect a missed meal dose* - the system provides insulin when users occasionally forget to bolus or underestimates the number of carbohydrates in their meal.

Recent MiniMed™ 780G system data from across Asia Pacific, demonstrates success in managing high carbohydrate diets, with users achieving outcomes similar to global users where high carbohydrate diets may not be as prevalent.²

Country	Sample Size (n)	Average Time in Range (TIR)	Average Time in Range with Recommended Settings (2-hour active insulin time and 100 mg/dL glucose target)
GLOBAL Users (from EMEA)	101,629	72.3%	78.8%
Japan	2030	72.3%	79.6%
India	1032	72.7%	76.8%
Singapore & Malaysia	160	75.4%	80.2%
Hong Kong	177	72.7%	80.0%

"Historically, people living with diabetes have been advised to change their lifestyle and adopt lower carb diets, which can impact their connection to cultural traditions. This is especially a challenge in Asian cultures where many meals are high in carbohydrates, requiring those who live with diabetes to interrupt mealtime routines to focus on their diabetes," said Robert Vigersky, chief medical officer, Medtronic Diabetes. "With the MiniMed™ 780G system, these disruptions can be avoided while glycemic control is maintained because the system can adapt to high carbohydrate meals. This permits people with diabetes to have the flexibility of living life as they want."

In real-world data across Asia Pacific (n=17,226) users had an average TIR of 70.7% and 76.3% TIR when using recommended optimal settings, with consistent results across different regions, underscoring the MiniMed™ 780G system's efficiency and adaptability to dietary variations, reinforcing its effectiveness in managing diabetes in diverse populations and cultures.

Economic Benefits of Diabetes Technology

Two budget impact analyses were presented demonstrating the cost-savings of Medtronic's MiniMed™ 780G system and Continuous Subcutaneous Insulin Infusion (CSII) pump in Singapore.

The budget impact analysis on the Medtronic Continuous Subcutaneous Insulin Infusion (CSII) pump will be shared at ATTD Asia during a short oral presentation. The study found that CSII pump with self-monitoring blood glucose (SMBG) led to significant cost savings compared to multiple daily injections (MDI) with SMBG. The CSII with SMBG, which is subsidized by the Singapore government, resulted in a reduction of HbA1c by 0.8% and severe hypoglycemia events by 0.41 per patient, per year, resulting in an estimated cost saving of SGD $6,066 per patient over 5 years. These savings are attributed to the reduction in diabetes-related complications, underscoring the value that diabetes technology has on patient experience, diabetes management, and healthcare systems.

"Policymakers across Asia have the chance to widen access and enhance the long-term health of their citizens. Embracing wider adoption of cost-effective diabetes technology today helps ensure a healthier future, fewer hospital visits, and better clinical outcomes," said Liz Carnabuci, VP, Diabetes APAC and Greater China.

This adds to data published earlier this year in Diabetes Technologies and Therapeutics that showed that the MiniMed™ 780G system is a cost-effective option for people with type 1 diabetes in Europe.

About Medtronic Diabetes (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

^* Taking a bolus 15 - 20 min before a meal helps to keep blood sugar levels under control after eating.
¹ Genuth S. Endocr Pract. 2006. 12(1): 34-41, DCCT Research Group. N Engl J Med. 1993;329:977-986.
² Choudhary, et. al. 2024 26(3): 32-37, Diabetes Technology & Therapeutics

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

For more information, contact:
Ashley Patterson
Global Communications
+1 (818) 576-3025

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626

Public link

Please use the above public link if you want to share this noodl on another website.